The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity

A mechanistic understanding of FOXL2C134W-induced regulatory state alterations drives discovery of a rationally designed therapeutic strategy. The somatic missense point mutation c.402C>G (p.C134W) in the FOXL2 transcription factor is pathognomonic for adult-type granulosa cell tumors (AGCT) and a diagnostic marker for this tumor type. However, the molecular consequences of this mutation and its contribution to the mechanisms of AGCT pathogenesis remain unclear. To explore these mechanisms, we engineered V5-FOXL2WT- and V5-FOXL2C134W–inducible isogenic cell lines and performed chromatin immunoprecipitation sequencing and transcriptome profiling. FOXL2C134W associated with the majority of the FOXL2 wild-type DNA elements as well as a large collection of unique elements genome wide. This model enabled confirmation of altered DNA-binding specificity for FOXL2C134W and identification of unique targets of FOXL2C134W including SLC35F2, whose expression increased sensitivity to YM155. Our results suggest FOXL2C134W drives AGCT by altering the binding affinity of FOXL2-containing complexes to engage an oncogenic transcriptional program. Significance: A mechanistic understanding of FOXL2C134W-induced regulatory state alterations drives discovery of a rationally designed therapeutic strategy.

[1]  D. Hyman,et al.  First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors , 2019, Clinical Cancer Research.

[2]  Donna D. Zhang,et al.  NRF2 and the Hallmarks of Cancer. , 2018, Cancer cell.

[3]  A. Iwase,et al.  FOXL2C134W-Induced CYP19 Expression via Cooperation With SMAD3 in HGrC1 Cells , 2018, Endocrinology.

[4]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[5]  Xiaoyan Li,et al.  Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor‐β type I receptor/apoptosis signal‐regulating kinase 1/mitogen‐activated protein kinase signaling axis , 2018, Cancer science.

[6]  David R. Kelley,et al.  Genetic determinants and epigenetic effects of pioneer factor occupancy , 2018, Nature Genetics.

[7]  M. Hirst,et al.  Generation of Native Chromatin Immunoprecipitation Sequencing Libraries for Nucleosome Density Analysis , 2017, Journal of visualized experiments : JoVE.

[8]  Michael D. Nyquist,et al.  Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155 , 2017, Molecular Cancer Research.

[9]  M. Hirst,et al.  Nucleosome Density ChIP-Seq Identifies Distinct Chromatin Modification Signatures Associated with MNase Accessibility. , 2016, Cell reports.

[10]  A. Talhouk,et al.  Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. , 2016, Journal of the National Cancer Institute.

[11]  Mark N. Wass,et al.  Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance , 2016, Cell Death and Disease.

[12]  I. Goldstein,et al.  Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions , 2016, Cell.

[13]  Fidel Ramírez,et al.  deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..

[14]  Y. Liu,et al.  MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1. , 2015, Molecular medicine reports.

[15]  M. Marra,et al.  MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation , 2015, Nature Communications.

[16]  Fan Mo,et al.  The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors12 , 2015, Neoplasia.

[17]  Qing-Yu He,et al.  ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization , 2015, Bioinform..

[18]  Eva Martínez-Peñafiel,et al.  Molecular Analysis by Gene Expression of Mitochondrial ATPase Subunits in Papillary Thyroid Cancer: Is ATP5E Transcript a Possible Early Tumor Marker? , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[19]  R. Veitia,et al.  The transcription factor FOXL2 mobilizes estrogen signaling to maintain the identity of ovarian granulosa cells , 2014, eLife.

[20]  H. Chiou,et al.  CHRNA9 polymorphisms and smoking exposure synergize to increase the risk of breast cancer in Taiwan. , 2014, Carcinogenesis.

[21]  Doris Chen,et al.  The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. , 2014, Nature chemical biology.

[22]  Steven J. M. Jones,et al.  JAGuaR: Junction Alignments to Genome for RNA-Seq Reads , 2014, PloS one.

[23]  S. Shimasaki,et al.  Granulosa cell tumor mutant FOXL2C134W suppresses GDF-9 and activin A-induced follistatin transcription in primary granulosa cells , 2013, Molecular and Cellular Endocrinology.

[24]  S. Shimasaki,et al.  Essential but differential role of FOXL2wt and FOXL2C134W in GDF-9 stimulation of follistatin transcription in co-operation with Smad3 in the human granulosa cell line COV434 , 2013, Molecular and Cellular Endocrinology.

[25]  B. Benayoun,et al.  Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation , 2013, Oncogene.

[26]  D. Huntsman,et al.  FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines , 2013, Modern Pathology.

[27]  P. Leung,et al.  Overexpression of Wild-Type but Not C134W Mutant FOXL2 Enhances GnRH-Induced Cell Apoptosis by Increasing GnRH Receptor Expression in Human Granulosa Cell Tumors , 2013, PloS one.

[28]  A. Shelling,et al.  The Transcriptional Targets of Mutant FOXL2 in Granulosa Cell Tumours , 2012, PloS one.

[29]  F. Jiang,et al.  Small nucleolar RNAs in cancer. , 2012, Biochimica et biophysica acta.

[30]  Jun Wang,et al.  Highly expressed SLC35F2 in non-small cell lung cancer is associated with pathological staging. , 2011, Molecular medicine reports.

[31]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[32]  Kangseok Lee,et al.  Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W) , 2011, Oncogene.

[33]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[34]  E. Simpson,et al.  Aromatase Is a Direct Target of FOXL2: C134W in Granulosa Cell Tumors via a Single Highly Conserved Binding Site in the Ovarian Specific Promoter , 2010, PloS one.

[35]  J. Carroll,et al.  FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response , 2010, Nature Genetics.

[36]  Galt P. Barber,et al.  BigWig and BigBed: enabling browsing of large distributed datasets , 2010, Bioinform..

[37]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[38]  P. Mellon,et al.  FoxL2 Is required for activin induction of the mouse and human follicle-stimulating hormone beta-subunit genes. , 2010, Molecular endocrinology.

[39]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[40]  B. Benayoun,et al.  Functional Exploration of the Adult Ovarian Granulosa Cell Tumor-Associated Somatic FOXL2 Mutation p.Cys134Trp (c.402C>G) , 2010, PloS one.

[41]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[42]  Ryan D. Morin,et al.  Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.

[43]  P. Lamba,et al.  A novel role for the forkhead transcription factor FOXL2 in activin A-regulated follicle-stimulating hormone beta subunit transcription. , 2009, Molecular endocrinology.

[44]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[45]  W. Fischer,et al.  FoxL2 and Smad3 Coordinately Regulate Follistatin Gene Transcription* , 2009, Journal of Biological Chemistry.

[46]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[47]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[48]  A. Kibel,et al.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. , 2007, Human molecular genetics.

[49]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[50]  J. Dausset,et al.  Potential targets of FOXL2, a transcription factor involved in craniofacial and follicular development, identified by transcriptomics , 2007, Proceedings of the National Academy of Sciences.

[51]  B. Ellsworth,et al.  The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein , 2003, Molecular and Cellular Endocrinology.

[52]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[53]  A. Leminen,et al.  Nationwide data on falling incidence of ovarian granulosa cell tumours concomitant with increasing use of ovulation inducers. , 1998, Human reproduction.

[54]  P. Leung,et al.  Long-term growth and steroidogenic potential of human granulosa-lutein cells immortalized with SV40 large T antigen , 1996, Molecular and Cellular Endocrinology.

[55]  W. Knöchel,et al.  Five years on the wings of fork head , 1996, Mechanisms of Development.

[56]  R. Pictet,et al.  Hepatocyte nuclear factor 3 determines the amplitude of the glucocorticoid response of the rat tyrosine aminotransferase gene. , 1995, DNA and cell biology.

[57]  P. Carlsson,et al.  Cloning and characterization of seven human forkhead proteins: binding site specificity and DNA bending. , 1994, The EMBO journal.

[58]  R. Costa,et al.  The DNA-binding specificity of the hepatocyte nuclear factor 3/forkhead domain is influenced by amino-acid residues adjacent to the recognition helix , 1994, Molecular and cellular biology.

[59]  S. Burley,et al.  Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5 , 1993, Nature.

[60]  D Weigel,et al.  The fork head domain: A novel DNA binding motif of eukaryotic transcription factors? , 1990, Cell.

[61]  D. Prescott,et al.  An evaluation of the double thymidine block for synchronizing mammalian cells at the G1-S border. , 1971, Experimental cell research.

[62]  A. Talhouk,et al.  FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. , 2017, The Journal of molecular diagnostics : JMD.

[63]  Y. Nishi,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Establishment and Characterization of a Steroidogenic Human Granulosa-Like Tumor Cell Line, KGN, That Expresses Functional Follicle-Stimulating Hormone Receptor , 2000 .

[64]  W. Knöchel,et al.  DNA recognition site analysis of Xenopus winged helix proteins. , 1995, Journal of molecular biology.